Intesticortmono

Budesonide, the active ingredient in Intesticortmono, is a corticosteroid presented as an oral formulation for systemic use. It is employed to reduce inflammation in specific gastrointestinal and esophageal disorders, particularly in adult patients with Crohn's disease, ulcerative colitis, or eosinophilic esophagitis.

GNH USA supplies Intesticortmono as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Intesticortmono (budesonide) is a glucocorticoid that targets inflammatory pathways in the gastrointestinal tract and esophagus. - Crohn's disease: helps achieve remission of intestinal inflammation and reduces symptoms such as abdominal pain and diarrhea. - Ulcerative colitis: contributes to mucosal healing and maintenance of remission in the colon. - Eosinophilic esophagitis: diminishes eosinophilic infiltration and improves swallowing difficulty.

Adverse reactions may occur with oral budesonide therapy.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Abdominal pain: cramping or discomfort in the abdomen. - Oral candidiasis: fungal infection of the mouth. - Increased appetite: may lead to weight gain. - Fatigue: feeling unusually tired.

Serious or Rare Side Effects: - Adrenal suppression: reduced endogenous cortisol production. - Severe infection: heightened risk of bacterial, viral, or fungal infections. - Hypersensitivity reactions: rash, itching, or anaphylaxis. - Osteoporosis: decreased bone mineral density with long‑term use. - Hyperglycaemia: elevated blood glucose levels, especially in diabetic patients. - Mood changes: depression, anxiety, or psychosis.

Before initiating therapy, clinicians should evaluate patient history and monitor for potential risks. - Infection risk: assess for active infections and avoid initiating therapy in uncontrolled infections. - Adrenal function: monitor cortisol levels during prolonged treatment. - Bone health: consider calcium and vitamin D supplementation for long‑term use. - Diabetes management: monitor blood glucose regularly. - Pregnancy and lactation: weigh benefits against potential risks; consult obstetric guidance. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Budesonide may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic exposure and risk of adverse effects. - Systemic immunosuppressants (e.g., azathioprine): additive immunosuppression heightening infection risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce budesonide levels, diminishing therapeutic effect. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase gastrointestinal irritation. - Anticoagulants (e.g., warfarin): may enhance anticoagulant effect, requiring INR monitoring. - Diuretics: potential for electrolyte imbalance when combined with systemic steroids.